The weekly litigation news digest is live. Subscribe now

IP Verse

Viiv Healthcare competitive analysis

Loading summary...

Latest patents of Viiv Healthcare opposed by its competitors

Explore Viiv Healthcare's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3494972
Dec 13, 2023Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv Infection10
EP3045206
Feb 15, 2023Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity1
EP3284520
Jun 5, 2019Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity1
EP3127542
Aug 22, 2018Antiviral Therapy4
EP2932970
Mar 21, 2018Antiviral Therapy2

Latest PTAB cases involving Viiv Healthcare

Discover the latest PTAB cases involving Viiv Healthcare, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 16, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Viiv Healthcare

IPR2015-00550Jan 8, 2015TEVA PHARMACEUTICALS USAVIIV HEALTHCAREInstitution Denied
IPR2014-00876Jun 2, 2014APOTEXVIIV HEALTHCARETerminated-Settled

Peer Comparison New

IP litigation analysis comparing Viiv Healthcare with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
VIIV HEALTHCARE - 18 - 2
COOKE27 - - -
GILEAD SCIENCES53186
TEVA PHARMACEUTICALS20916 - 12